Prostatype Genomics announces very high subscription rate

Prostatype Genomics AB announces very high subscription rate.
From the outstanding TO4 approximately 93.6 % were exercised including 5 % from the Top Guarantee. This constitutes an impressing support from the shareholders, and Life Science Invest Fund (LSIF) is pleased to announce, that we, being a major shareholder, subscribed to our pro rata share. We are now looking forward to receiving feed back from Medicare on the application submitted by Prostatype Genomics AB on September 30th. An approval is an extremely important milestone to achieve.